Open AccessResearch progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
Author(s) -
Li Tianjiao,
Li Hao,
Li Shuo,
Xu Shuaishuai,
Zhang Wuhu,
Gao Heli,
Xu Huaxiang,
Wu Chuntao,
Wang Wenquan,
Yu Xianjun,
Liu Liang
Publication year - 2019
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.2430
Subject(s) - chimeric antigen receptor , cancer research , medicine , tumor microenvironment , pancreatic cancer , stroma , pancreatic ductal adenocarcinoma , chemotaxis , cancer , adenocarcinoma , immunology , immunotherapy , immune system , receptor , tumor cells , immunohistochemistry
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant cancer with limited treatment options. Chimeric antigen receptor T cells (CAR‐T) are genetically engineered T cells that can specifically kill tumor cells without major histocompatibility complex restriction. Encouraging progress in CAR‐T therapy for PDAC has been made in preclinical and early phase clinical trials. Challenges in CAR‐T therapy for solid tumors still exist, including immunosuppressive microenvironment, interstitial barrier, poor chemotaxis, and the “on‐target, off‐tumor” effect. Applying neoantigens of PDAC as targets for CAR‐T therapy, recognizing the CAR‐T subgroup with better antitumor effect, and designing a CAR‐T system targeting stroma of PDAC may contribute to develop a powerful CAR‐T therapy for PDAC in the future.